Global Imiglucerase Market Strategic Research Report

Scope of the Report

The global Imiglucerase market size is predicted to grow from US$ 1,081 million in 2025 to US$ 1,449 million in 2032; it is expected to grow at a CAGR of 4.4% from 2026 to 2032.

Imiglucerase is a biological agent prepared using recombinant gene technology. It belongs to the category of enzyme replacement therapy drugs, and its core application is in the treatment of the rare disease Gaucher disease. Imiglucerase controls the disease at its metabolic root by artificially supplementing the missing enzyme, and is a core drug for treating type 1 and some types 3 Gaucher disease. Being a recombinant biological agent, it requires long-term intravenous infusion. Although it is relatively expensive, it effectively prevents organ damage and improves patient survival.

Imiglucerase, as a benchmark drug in the field of enzyme replacement therapy for Gaucher disease, is occupying a core position in the global and Chinese rare disease drug market, relying on its clear clinical value and stable demand. In terms of market size, the global and Chinese imiglucerase market had already reached a scale of hundreds of millions of yuan by 2024, and the global market is expected to continue to expand at a steady compound annual growth rate until 2030. This growth trend stems from the increased diagnosis rate of Gaucher disease patients, but even more so from the clinical trust established by the product in long-term treatment.

Currently, the global imiglucerase market is dominated by Sanofi. Through its acquisition of Genzyme, a benchmark company in the global rare disease field, in 2011, Sanofi incorporated imiglucerase (trade name: Cerezo®) into its core product portfolio. The research and development of this product can be traced back to the 1990s—in 1994, imiglucerase was first approved by the US FDA, becoming the first recombinant enzyme replacement therapy drug for the treatment of Gaucher disease, completely changing the predicament of Gaucher disease patients having no effective treatment options. In 2008, Sanofi facilitated the entry of imiglucerase into the Chinese market and obtained approval for its market launch. To date, Sanofi has established an imiglucerase production and supply system covering major global markets, with a sales and service network centered in core cities such as Beijing, Shanghai, and Guangzhou, radiating across the entire country in China alone.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Imiglucerase market?

What factors are driving Imiglucerase market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Imiglucerase market opportunities vary by end market size?

How does Imiglucerase break out by Type, by Application?

This report presents a comprehensive overview of the global Imiglucerase market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Type I Gaucher Disease
• Type III Gaucher Disease

Segment by Application

• Public Hospitals
• Private Hospitals

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Imiglucerase market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Public Hospitals, Private Hospitals evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact